Pelthos Therapeutics Joins The Russell 3000E Growth Benchmark, Russell Microcap And Russell Microcap Growth Benchmark Indexes

Pelthos Therapeutics Inc. (NYSE: PTHS ), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective when the US market opened on June 29 as part of the 2026 Russell indexes reconstitution.

The June Russell US Indexes reconstitution captures up to the 4,000 largest US stocks as of Thursday, April 30th, ranking them by total market capitalization.

Beginning in 2026, the Russell US Indexes are reconstituted on a semi-annual basis (in June and December), and membership in the Russell Microcap® Index remains in place until the next scheduled reconstitution.

Membership in the Russell Microcap® Index also means automatic inclusion in the appropriate growth and value style indexes.

FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.